Endovascular repair or open repair for ruptured abdominal aortic aneurysm: a Cochrane systematic review


Published in:
BMJ Open

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2016 the authors. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial license (http://creativecommons.org/licenses/by-nc/4.0/), which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person’s rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access
This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback
BMJ Open

Endovascular repair or open repair for ruptured abdominal aortic aneurysm: a Cochrane systematic review

S A Badger,1 D W Harkin,2 P H Blair,2 P K Ellis,2 F Kee,3 R Forster4

ABSTRACT

Objectives: Emergency endovascular aneurysm repair (eEVAR) may improve outcomes for patients with ruptured abdominal aortic aneurysm (RAAA). The study aim was to compare the outcomes for eEVAR with conventional open surgical repair for the treatment of RAAA.

Setting: A systematic review of relevant publications was performed. Randomised controlled trials (RCTs) comparing eEVAR with open surgical repair for RAAA were included.

Participants: 3 RCTs were included, with a total of 761 patients with RAAA.

Interventions: Meta-analysis was performed with fixed-effects models with ORs and 95% CIs for dichotomous data and mean differences with 95% CIs for continuous data.

Primary and secondary outcome measures: Primary outcome was short-term mortality. Secondary outcome measures included aneurysm-specific and general complication rates, quality of life and economic analysis.

Results: Overall risk of bias was low. There was no difference between the 2 interventions on 30-day (or in-hospital) mortality, OR 0.91 (95% CI 0.67 to 1.22; p=0.52). 30-day complications included myocardial infarction, stroke, composite cardiac complications, renal complications, severe bowel ischaemia, spinal cord ischaemia, reoperation, amputation and respiratory failure. Reporting was incomplete, and no robust conclusion was drawn. For complication outcomes that did include at least 2 studies in the meta-analysis, there was no clear evidence to support a difference between eEVAR and open repair. Longer term outcomes and cost per patient were evaluated in only a single study, thus precluding definite conclusions.

Conclusions: Outcomes between eEVAR and open repair, specifically 30-day mortality, are similar. However, further high-quality trials are required, as the paucity of data currently limits the conclusions.

BACKGROUND

Abdominal aortic aneurysm (AAA) affects between 1.2% and 7.6% of the population over 50 years of age in the UK. There has been recent decline in prevalence to about 2%. This is independent of participant selection criteria and reflects better cardiovascular risk profiling and management in the overall population.1 2 Unfortunately, many aneurysms first present as a rupture resulting in death in the majority of those affected.

The high mortality rate from ruptured AAA (RAAA) is well recognised. Clinicians have been reticent to apply scoring systems rigidly as to do so would condemn many to certain death.3–5 Patients who undergo successful open repair of RAAA enjoy a postoperative quality of life similar to the ‘normal population’.6 7 The risk of aneurysm rupture is proportional to aneurysm size, with aneurysms measuring less than 5.4 cm having an annual rupture rate of approximately 1% whereas those greater than 7.0 cm in diameter have an annual rupture rate of 32.5%.8 9 Currently, rupture leads to death in over 80% of those affected, including 30–65% of those who receive conventional open surgical repair and is responsible for 2.1% of all deaths in men over 65 years.10–12 These findings contrast with the significantly better outcome if conventional open surgical repair of the AAA is planned before rupture can occur.
Historically, open surgical repair was the only effective treatment for AAA. This major operation carries significant morbidity and mortality, due to the combined effects of surgical exposure, haemorrhage and aortic clamping with related lower torso ischaemia-reperfusion injury. However, with improved patient selection and perioperative care, some specialist centres are reporting mortality rates of less than 2% and surgeons in non-specialist units achieving mortality rates of 5–8%. However, in the past two decades, this treatment has been challenged by endovascular aneurysm repair (EVAR). Significant advancements in commercial stent design, delivery and implantation technique have made this a valuable alternative to open repair in selected suitable cases. Its use in elective cases has reduced early postoperative morbidity and mortality. Its minimally invasive nature allows it to be performed under regional or even local anaesthesia, rather than general anaesthesia. This allows repair in patients with significant concomitant medical disease who may otherwise have been considered unfit for surgery. Two recent large prospective randomised controlled trials (RCTs) have shown reduced early complications and mortality with EVAR. However, while elective endovascular repair clearly has a role, these trials reinforce the knowledge that open repair will remain the treatment for a large proportion of patients whose AAA is unsuitable on anatomical grounds for EVAR. In addition, long-term results from the EVAR 1 trial should add caution, with later ruptures in the EVAR group, and no long-term difference in the all-cause mortality.

Rupture of an AAA (RAAA) is a catastrophic event, with up to 80% mortality. RAAA exposes the patients to the combined injury of a period of haemorrhagic shock and lower torso ischaemia followed by a reperfusion injury on successful revascularisation. This 'two hit' mechanism of injury initiates a systemic inflammatory response syndrome, leading to a multiple organ dysfunction syndrome (MODS). MODS is the primary cause of 70% of such deaths and a contributory cause of the remainder. The multiorgan failure, despite intensive care support, once established leads to death in over 70% of cases. EVAR, especially under local anaesthesia, reduces the physiological insult to the body as compared with conventional open surgical repair. Emergency EVAR (eEVAR) appears to offer a feasible alternative to conventional open repair in selected patients. Emergency cases were repaired with an aortouniliac stent graft, contralateral occluder and fem-fem crossover in the initial years, due to increased speed of

---

**Figure 1** PRISMA flow chart of literature selection. TSC, Trials Search Co-ordinator.
achieving a seal and haemodynamic stability. However, the use of bifurcated stent graft is routine for ruptured AAA. Early reports have suggested a trend towards reduction in perioperative morbidity and mortality in selected patients. Indeed evidence is emerging that the inflammatory response to RAAA repair and the associated organ dysfunction is attenuated by eEVAR compared with open repair.31 32

The purpose of this review was to assess the available evidence to support the use of eEVAR to treat RAAA. The advantages and disadvantages of eEVAR for patients with RAAA was determined by the effect on short-term mortality, major complication rates, aneurysm exclusion and late complications when compared with patients who have had conventional open repair of RAAA. The results of this review have been published as a Cochrane review, which was an update of the initial study.33 34

**METHODS**

Only prospective RCTs comparing eEVAR with conventional open surgical repair were considered eligible for inclusion. Within the studies, all patients in whom a RAAA has been clinically diagnosed by CT, angiography, MR angiography or objective acute symptoms suggestive of impending rupture of the aneurysm to warrant inclusion. Only prospective RCTs comparing eEVAR with conventional open surgical repair were considered eligible for inclusion. Within the studies, all patients in whom a RAAA has been clinically diagnosed by CT, angiography, MR angiography or objective acute symptoms suggestive of impending rupture of the aneurysm to warrant inclusion. All types of endovascular devices were considered in comparison with conventional open surgical treatment for patients considered fit for surgery.

The primary outcome for the study was the short-term morality (30-day, or in-hospital mortality). Secondary outcomes included:

- Aneurysm exclusion, or further extravasation beyond the sac on follow-up imaging 30 days after the procedure;
- Major complications, such as open conversion, haemorrhage, myocardial infarction, stroke, renal failure (20% rise in creatinine levels), respiratory failure (requirement for postoperative mechanical ventilation), pneumonia, bowel ischaemia, lower limb ischaemia;
- Minor complications, such as catheter site haematoma, wound infection;
- Long-term complications and mortality; re-intervention rates for problems related to the RAAA or its treatment will be sought where possible, as will cause of death, with or without re-intervention, that is, device related;
- Quality of life (standardised questionnaires);
- Economic analysis (cost per patient).

**SEARCH METHODS**

For this update, the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched February 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2014, Issue 2, part of The Cochrane Library.35 The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED and through hand searching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the Specialised Register section of the Cochrane Peripheral Vascular Diseases Group module in The Cochrane Library.35 36 References of relevant studies were reviewed for other pertinent publications.

**Data collection and extraction**

Two authors (SAB and RB) independently reviewed the studies identified by the search for their relevance using the selection criteria. Disagreements were resolved through discussion. Two review authors (SAB and RB) independently extracted data for each included study.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>The string search performed of the terms in the literature</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>MeSH descriptor: [Ednovascular Procedures] explode all trees</td>
</tr>
<tr>
<td>#2</td>
<td>MeSH descriptor: [Stents] explode all trees</td>
</tr>
<tr>
<td>#3</td>
<td>MeSH descriptor: [Vascular Surgical Procedures] this term only</td>
</tr>
<tr>
<td>#4</td>
<td>Endovasc:ti,ab,kw</td>
</tr>
<tr>
<td>#5</td>
<td>Endostent*:ti,ab,kw</td>
</tr>
<tr>
<td>#6</td>
<td>Endograft*</td>
</tr>
<tr>
<td>#7</td>
<td>EVRAR:ti,ab,kw</td>
</tr>
<tr>
<td>#8</td>
<td>(EVAR or REVAR):ti,ab,kw</td>
</tr>
<tr>
<td>#9</td>
<td>(Palmaz):ti,ab,kw</td>
</tr>
<tr>
<td>#10</td>
<td><em>stent</em> or graft*</td>
</tr>
<tr>
<td>#11</td>
<td>Palmaz:ti,ab,kw</td>
</tr>
<tr>
<td>#12</td>
<td>Viabahn or Nitinol or Hemobahn or Intracoil or Tantalum or powerlink or excluder or talent or aorfix or endologix or anaconda:ti, ab,kw</td>
</tr>
<tr>
<td>#13</td>
<td>Zenith or Dynalink or Hemobahn or Luminex or Memotherm or Wallstent:ti,ab,kw</td>
</tr>
<tr>
<td>#14</td>
<td>MeSH descriptor: [Blood Vessel Prosthesis] explode all terms</td>
</tr>
<tr>
<td>#15</td>
<td>MeSH descriptor: [Blood Vessel Prosthesis Implantation] this term only</td>
</tr>
<tr>
<td>#16</td>
<td>Endoprosthesist:ti,ab,kw</td>
</tr>
<tr>
<td>#17</td>
<td>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16</td>
</tr>
<tr>
<td>#18</td>
<td>MeSH descriptor: [Aneurysm, Ruptured] explode all terms</td>
</tr>
<tr>
<td>#19</td>
<td>MeSH descriptor: [Aneurysm, Dissecting] this term only</td>
</tr>
<tr>
<td>#20</td>
<td>(aneurysm* or abdom* or thoracoabdom* or thorac-abdom* or aort*) near (ruptur* or tear or bleed* or trauma)</td>
</tr>
<tr>
<td>#21</td>
<td>MeSH descriptor: [Aorta] explode all terms and with qualifier(s): [Surgery—SU]</td>
</tr>
<tr>
<td>#22</td>
<td>RAAA</td>
</tr>
<tr>
<td>#23</td>
<td>#18 or #19 or #20 or #21 or #22</td>
</tr>
<tr>
<td>#24</td>
<td>#17 and #23 in Trials</td>
</tr>
</tbody>
</table>
### Table 2  The details of the Hinchcliffe study

| Methods | Study type: single-centre, randomised controlled trial, open label, intention-to-treat  
Study aim: to test the hypothesis that EVAR can reduce the perioperative mortality of ruptured AAA, compared with open repair  
Country: England  
Setting: hospital |
|---|---|
| Participants | Number randomised: total n=32 (eEVAR n=15; open repair n=17)  
Gender (M/F): eEVAR=11/4; open repair=13/4  
Inclusion criteria: all patients admitted with clinically suspected or radiologically confirmed rupture of an infrarenal abdominal aortic aneurysm that, in the opinion of the duty consultant vascular surgeon would normally be treated with open repair  
Exclusion criteria: no endovascular team available; full selection of emergency stent grafts not available; age <50 years; inability to give verbal or written consent; unconscious patient; allergy to radiological contrast, stainless steel or polyester; severe comorbidity that would preclude intensive care treatment following open repair; previous endovascular AAA repair; women of childbearing potential not taking contraception; pregnant and lactating women |
| Interventions | eEVAR description: those with a diagnostic CT were transferred directly to operating theatre, and those without first had a CT scan to determine aortic measurement; performed in dedicated vascular operating theatre using a Siremobil 2000 image intensifier, with digital subtraction angiography facilities; most patients heparinised; two-piece aortouniiliac stent graft made with Gianturco stents with uncovered suprarenal component; occluding device used in contralateral common iliac artery; after deployment of stent graft, a femoro-femoral crossover graft was performed  
Open repair description: after randomisation to open repair, patients were transferred directly to the operating theatre, according to local practice; performed transperitoneally either by midline or transverse incisions; aorta clamped below renal arteries; patients no heparinised; inlay technique was used and grafts were gelatin-coated polyester |
| Outcomes | Perioperative mortality, defined as 30-day or in-hospital |
| Notes | ‘Patients were deemed suitable for EVAR if, in the opinion of the operating surgeon, they could perform the repair’; participants recruited September 2002 to December 2004; five surgeons on unit, required that surgeon and team available had sufficient expertise to offer EVAR, if not, conventional open repair was offered; unstable patients that might be disadvantaged by delay incurred by CT scan could, at the surgeon’s discretion, not be randomised and taken directly for open repair |

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Bias</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>‘Randomisation was then performed from sealed opaque envelopes kept in the Accident and Emergency Department’. Unclear how randomisation sequence was generated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>‘Randomisation was then performed from sealed opaque envelopes kept in the Accident and Emergency Department’</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias); all outcomes</td>
<td>Low risk</td>
<td>Study was unblinded, due to nature of intervention but unlikely to influence outcomes. ‘The surgeons were blinded to the dimensions of patient’s aorta until randomisation had taken place’ to avoid bias</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias); all outcomes</td>
<td>Low risk</td>
<td>Not possible to blind team regarding allocation group, but unlikely to influence outcome measures</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias); all outcomes</td>
<td>Low risk</td>
<td>All patients accounted for; crossover patients accounted for; similar dropout rates and reasons between treatment groups</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Most of the protocol outlined in the text; all relevant outcomes reported; with the exception of mortality, outcomes are not well described in the methods</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Underpowered study: 32 of the required 100 patients recruited</td>
</tr>
</tbody>
</table>

AAA, abdominal aortic aneurysm; eEVAR, emergency endovascular aneurysm repair; F, female; M, male.
### Table 3  The details of the Amsterdam Acute Aneurysm Trial (AJAX) study

**Methods**  
Study type: multicentre, randomised controlled trial, intention-to-treat  
Study aim: compare EVAR and open repair in treating RAAA on mortality and severe complications  
Country: The Netherlands  
Setting: three large hospital vascular centres in Amsterdam  
Number randomised: total n=116 (eEVAR n=57; open repair n=59)  
Age (mean years, 95% CI): eEVAR=74.5 (72.3 to 77.5); open repair=74.5 (72.2 to 76.8)  
Gender (M/F): eEVAR=49/8; open repair=50/9  
Inclusion criteria: male and females over 18 years; clinical diagnosis of RAAA; aneurysm accompanied by acute haemorrhage outside of the aortic wall of CTA; suitable for eEVAR and open repair  
Exclusion criteria: extension of the aneurysm to juxtarenal or suprarenal aorta; kidney transplant; horseshoe kidney; allergy to intravenous contrast; connective tissue disease; severe haemodynamic instability prohibiting CT  
eEVAR anatomical suitability requirements: suitable infrarenal anchoring segment, minimum length of the infrarenal segment of at least 10–15 mm, infrarenal diameter of 20–32 mm, no obstructing calcifications, tortuosity of thrombosis, suitable iliac anchoring segment, ipsilateral iliac diameter of 8–18 mm, contralateral iliac diameter of 10–20 mm, at least one iliac artery should be able to accommodate an endograft  
CVD risk factors (n (%)): diabetes (EVAR n=2 (4%), open repair n=1 (2%)); hypertension (EVAR n=13 (23%), open repair n=10 (17%)); smoker (EVAR n=23 (40%), open repair n=20 (34%)); hyperlipidaemia (EVAR n=13 (23%), open repair n=19 (32%)); renal disease (EVAR n=1 (2%), open repair n=2 (3%)); pulmonary disease (EVAR n=7 (12%), open repair n=3 (5%)); carotid disease (EVAR n=16 (28%), open repair n=10 (17%)); cardiac disease (EVAR n=16 (28%), open repair n=14 (24%))  
Type of RAAA: infrarenal  

**Interventions**  
eEVAR description: aortouniiliac endograft and contralateral iliac occluding device, followed by a femoro-femoral crossover bypass graft  
Open repair description: midline laparotomy and exclusion of rupture aneurysm by either polyester tube or bifurcated graft; conducted under general anaesthesia  

**Outcomes**  
Composite death and severe complications at 30 days after intervention; long-term mortality rates (6 months after randomisation); length of hospital and ICU stay; duration of intubation/ventilation; use of blood products; for EVAR, occurrence of endoleaks  

**Notes**  
Study period: April 2004 to February 2011; three main trial centres, all other (seven) regional hospitals transferred participants to one of the trial centres  

**Risk of bias**  
Bias  
Authors’ judgement  
Support for judgement  
Random sequence generation (selection bias)  
Low risk  
‘The randomization sequence was generated by an independent clinical research unit using ALEA software for randomization in clinical trials with a 1:1 allocation using random block sizes of 4 or 6, stratified for each participating centre’  
Allocation concealment (selection bias)  
Low risk  
‘Allocation was concealed using sequentially numbered opaque sealed envelopes’  
Blinding of participants and personnel (performance bias); all outcomes  
Low risk  
Surgical team not possible to blind, but unlikely to influence outcomes  
Blinding of outcome assessment (detection bias); all outcomes  
Low risk  
Double database entry; end point adjudication committee blinded; independent safety committee blinded  
Incomplete outcome data (attrition bias); all outcomes  
Low risk  
All patients accounted for in CONSORT diagram; both treatment groups had similar dropout rates and reasons  
Selective reporting (reporting bias)  
Unclear risk  
Although all prespecified outcomes listed in the Reimerink publication are reported, quality of life and cost-effectiveness as described in the study protocol, were not included, suggesting further publications to emerge  
Other bias  
Low risk  
None  

CVD, cardiovascular disease; eEVAR, emergency endovascular aneurysm repair; F, female; ICU, intensive care unit; M, male; RAAA, ruptured abdominal aortic aneurysm.
Details about the trial design, characteristics of participants, diagnosis of RAAA, eEVAR and open repair procedures were recorded. Data were collected on the primary outcome short-term mortality (30-day or in-hospital) and secondary outcomes: aneurysm exclusion, major and minor short-term complications, long-term all-cause mortality and long-term complications, quality of life, and economic analysis. If data were missing from publications of the included studies, attempts were made to contact study authors.

Table 4  The details of the Immediate Management of the Patient with Rupture: Open Versus Endovascular (IMPROVE) study

<table>
<thead>
<tr>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study type: multicentre, randomised controlled trial, open label, intention-to-treat</td>
</tr>
<tr>
<td>Study aim: to assess whether EVAR vs open repair reduces early mortality for patients with suspected RAAA</td>
</tr>
<tr>
<td>Country: UK and Canada</td>
</tr>
<tr>
<td>Setting: 30 hospital vascular units and specialist centres</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number randomised: total n=613 (eEVAR n=316; open repair n=297)</td>
</tr>
<tr>
<td>Age (mean years (±SD)): eEVAR=76.7 (7.4); open repair=76.7 (7.9)</td>
</tr>
<tr>
<td>Gender (M/F): eEVAR=246/70; open repair=234/63</td>
</tr>
<tr>
<td>Inclusion criteria: men and women over the age of 50 years; clinical diagnosis of RAAA or ruptured aortoiliac aneurysm, made by a senior trial hospital clinician</td>
</tr>
<tr>
<td>Exclusion criteria: previous aneurysm repair; rupture of an isolated internal iliac aneurysm, aortocaval or aortoenteric fistulae; recent anatomical assessment of the aorta; connective tissue disorder; if intervention was considered futile</td>
</tr>
<tr>
<td>eEVAR anatomical suitability requirements: no absolute requirements will be set for the study, but proximal neck morphology with a diameter exceeding 32 mm or a length less than 10 mm may be considered unfavourable, and iliac artery diameters should be in the range of 8–22 mm</td>
</tr>
<tr>
<td>CVD risk factors (n (%)): not given</td>
</tr>
<tr>
<td>Type of RAAA: ‘ruptured AAA or ruptured aortoiliac aneurysm’</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>eEVAR description: endovascular supracoeliac aortic balloon occlusion will be used to support less stable patients; most interventions performed with aortouniiliac graft, but some patients received bifurcated grafts, with subsequent femoro-femoral crossover graft with contralateral iliac occlusion; control of aorta achieved using local/region anaesthesia, with general anaesthesia used later in procedure if necessary Open repair description: CT scan is optional; aneurysms repaired by cross-clamping the proximal aorta and inserting a prosthetic inlay graft; performed under general anaesthesia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>30-day mortality, 24 h and in-hospital mortality, costs, reinterventions at primary admission time and place of discharge; cost-effectiveness and mortality at 12 months are planned for future reporting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants recruited September 2009 to July 2013; flow diagram shows 623 randomised, but 10 were excluded after Data Monitoring Committee reviewed participants, 613 used in analysis; only 275 (87%) of EVAR and 261 (88%) of open repair had confirmed RAAA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bias</td>
</tr>
<tr>
<td>Random sequence generation (selection bias)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias); all outcomes</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias); all outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias); all outcomes</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
</tr>
<tr>
<td>Other bias</td>
</tr>
<tr>
<td>CVD, cardiovascular disease; eEVAR, emergency endovascular aneurysm repair; F, female; M, male; RAAA, ruptured abdominal aortic aneurysm.</td>
</tr>
</tbody>
</table>

Assessment of risk of bias in included studies
Included studies were evaluated for quality, independently by two review authors (SAB and RB), using The Cochrane Collaboration’s tool for assessing risk of bias.36 This tool provides judgements made on the domains of sequence generation, allocation concealment methods, blinding, incomplete outcome data, selective outcome reporting and other relevant biases. Evaluations of low risk, unclear risk or high risk were given for each of the six domains for each included study. Any disagreements between review authors were resolved through discussion.

Measures of treatment effect
Analysis was planned on an intention-to-treat basis, and therefore all randomised patients from the included studies were to be included in analysis. The outcomes that are dichotomous in nature were to be compiled into meta-analysis and ORs with 95% CIs were to be calculated. For continuous data, meta-analysis would provide mean differences with SDs.

Assessment of heterogeneity
A test for heterogeneity examines the null hypothesis that all studies are evaluating the same effect. We obtained p values comparing the test statistic with a χ² distribution. A measure (I²) that describes the percentage of total variation across studies due to heterogeneity rather than by chance was included. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity.37

Data synthesis
Data extracted independently by two review authors (SAB and RB) was compiled and entered into RevMan by one author (RB). Comparisons of data using meta-analyses were undertaken using fixed-effects models, unless the test for heterogeneity yielded a value >50%, in which case a random-effects model was implemented.

Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis to evaluate the impact of patients treated with aortouniiliac devices and those treated with aortobibiliac devices. The Amsterdam Acute Aneurysm Trial (AJAX) and Hinchcliffe trials only used aortouniiliac devices, while the Immediate Management of the Patient with Rupture: Open Versus Endovascular (IMPROVE) used both methods, with a greater proportion being aortobibiliac.38–48 However, due to a paucity of information, subgroup analysis was not possible at this time.

Sensitivity analysis
Although all the participants in the IMPROVE trial had a clinical diagnoses of RAAA, on start of the intervention, it was found that only 536 (87%) of the 613 randomised participants had, in fact, a ruptured AAA.46 48 Of the remaining 77 participants, 22 had symptomatic non-ruptured AAA, or other final diagnoses. Sensitivity analyses were planned to evaluate the effects of this trial on the outcomes.

RESULTS
A total of 18 new citations were identified in the search. Four were considered not relevant as they were reviews, and two were added to the excluded studies.49 50 One study, Endovasculaire ou Chirurgie dans les Anevrismes aorto-iliaques Rompus (ECAR), fits the inclusion criteria, but is currently ongoing, with no published data at this time.51–53 Ten citations, from three studies, were newly included.36–48 Five prospective comparative studies were excluded.29 49 50 54 55 The flow of included and excluded studies is illustrated by means of a PRISMA diagram (figure 1). The search string results are presented in table 1.

The three included studies had a total of 761 participants.38–48 All three studies were RCTs comparing eEVAR to open surgery repair in patients with a clinical diagnosis of RAAA on outcomes that included mortality and complications. AJAX and IMPROVE aimed to evaluate longer term mortality and complications, but at the time of this review, there was no long-term data published from the IMPROVE trial. Also, the IMPROVE trial evaluated cost-effectiveness by comparing cost-per-patient between the two trial arms. Currently none of the included studies have evaluated aneurysm exclusion, minor complications or quality of life.

![Figure 2](image_url) Short-term mortality (30-day or in-hospital) of emergency endovascular aneurysm repair (eEVAR) versus open repair.

![Figure 3](image_url) Myocardial infarction of emergency endovascular aneurysm repair (eEVAR) versus open repair.
AJAX and IMPROVE were both multicentre studies, with AJAX taking place in Amsterdam, the Netherlands, and IMPROVE in the UK, with one study site in Canada. Hinchliffe et al was a single-centre trial within England. All included participants had a clinical diagnosis of RAAA, but in the IMPROVE study only 536 out of the 613 (87%) randomised participants actually had RAAA, the remaining 77 had symptomatic non-ruptured AAA (22), no AAA (10), or asymptomatic AAA or another final diagnosis (45). For the AJAX study, all randomised participants were considered suitable for both eEVAR and open repair, which in the Hinchliffe and IMPROVE studies suitability for eEVAR was determined after randomisation. In the Hinchliffe and AJAX studies, aortouniiliac grafts were used in the endovascular trial arm, while the IMPROVE trial used both this and, more predominately, aortobiiliac grafts. The data derived from the three studies are outlined in tables 2–4 with quality of data described.

Five studies were excluded from this review. Three studies were prospective trials, treating patients presenting with RAAA with eEVAR. However, their comparison to open repair was made through retrospective, ‘historical controls’ or with open repair cohorts. One study was a prospective comparison between eEVAR and open repair in patients with RAAA, but the study was non-randomised. A final study was a non-randomised study of 55 consecutive patients presenting with RAAA. A portion of the participants in the study were collected retrospectively and a portion prospectively.

Allocation (selection bias)
Both the AJAX and IMPROVE studies adequately reported random sequence generation, but the Hinchliffe study did not give a description of how their sequence was produced, and is therefore at unclear risk. For allocation concealment, all three studies clearly explained adequate concealment methods.

Blinding (performance bias and detection bias)
Owing to the nature of the intervention, it is not possible to blind the surgeons and difficult to blind patients and the research team to the treatment allocation. However, we determined that a lack of blinding is unlikely to influence the outcomes of interest, and all three have been listed as low risk for performance and detection bias. Attempts were made to reduce the risk of bias by the study authors: in the AJAX study, an endpoint adjudication committee and independent safety committee, both blinded to treatment allocation, were utilised. The Hinchliffe study kept surgeons blinded to the dimensions of the aorta until randomisation was completed, and the IMPROVE study utilised a trial core laboratory to centrally verify outcomes.

Incomplete outcome data (attrition bias) and selective reporting (reporting bias)
All three included studies adequately accounted for all participants, giving thorough explanation of all dropout rates and reasons. All three studies were at a low risk of attrition bias. Both the AJAX and IMPROVE trials are lacking important outcome data specified in their protocols, which include quality of life and costs for both studies, and complications and long-term survival for the IMPROVE study. It is assumed that these outcomes will be reported in future publications, but until that data are reported, the two studies are at an unclear risk of reporting bias. The Hinchliffe study reported on all outcomes specified.

Other potential sources of bias
The AJAX and IMPROVE studies appear to be free of other sources of bias, but the Hinchliffe study could be at risk of bias due to an underpowered study population. In the publication, it was reported that the study
required 100 participants to be adequately powered, yet they only included 32 patients.

EFFECTS OF INTERVENTIONS
Mortality (30-day or in-hospital)
All three studies were included in the meta-analysis for mortality (30-day or in-hospital). The fixed-effects model found no clear evidence to support a difference in mortality between eEVAR and open repair, OR 0.93 (95% CI 0.69 to 1.25; p=0.63; figure 2). When the IMPROVE study was removed for sensitivity analysis, due to randomisation of patients that did not have RAAA, the OR moved closer to one and the CI became wider as the IMPROVE study had a larger study population than the other two included studies, OR 0.98 (95% CI 0.49 to 1.95; p=0.95).

Complications (30-day)
Myocardial infarction
Only the Hinchliffe study reported myocardial infarction, but only one event was reported so the CI is very wide, OR 3.62 (95% CI 0.14 to 95.78; figure 3). As only one study was included for this outcome, no overall association could be determined, and the wide CI makes any conclusion spurious.

Stroke
Both the AJAX and Hinchliffe studies reported stroke events, but with very few events, and opposing findings, the fixed-effects model, with a non-significant OR has a very wide CI that is difficult to derive any meaningful conclusion from (OR 0.71, 95% CI 0.12 to 4.31; p=0.71; figure 4).

Cardiac complications (moderate or severe)
Cardiac complications were evaluated in the AJAX and Hinchliffe studies. The fixed-effects meta-analysis found a non-significant OR, but again with a wide CI (OR 1.12, 95% CI 0.38 to 3.30; p=0.84; figure 5).

Renal complications (moderate or severe)
The AJAX and Hinchliffe studies reported renal complications, and the random-effects model used to analyse the association found no clear difference between the interventions, OR 0.70 (95% CI 0.09 to 5.24; p=0.73; figure 6).

Severe bowel ischaemia
Only a single study evaluated severe bowel ischaemia (AJAX), which had an OR of 0.39 (95% CI 0.07 to 2.11), but as only one study was included, no overall association could be determined (figure 7).

Spinal cord ischaemia
Spinal cord ischaemia was also only evaluated in the AJAX study, which had only one event. With an OR of 3.16 and a 95% CI of 0.13 to 79.17, very little can currently be concluded regarding this outcome (figure 8).

Reoperation
The occurrence of reoperation, specific to the aneurysm repair, was reported in two studies (AJAX and Hinchliffe). The fixed-effects model did not find clear evidence to support a difference between the interventions, OR 0.89 (95% CI 0.39 to 2.01; p=0.78), again with a rather wide CI (figure 9).

Amputation
The AJAX trial was the only study to evaluate amputation, and with the few events, all in the open repair intervention group, the OR of 0.14 (95% CI 0.01 to 2.78) had a wide CI and no association to be concluded, as only a single study was included (figure 10).

Respiratory failure
Respiratory failure was evaluated in the Hinchliffe study, alone. With only a single event in the eEVAR arm, the CI was very wide, OR 3.62 (95% CI 0.14 to 95.78) with no overall association (figure 11).
Long-term outcomes (6 months)

Long-term outcomes were only evaluated in the AJAX study. There was no clear evidence to support a difference between the interventions for mortality at 6 months in the eEVAR arm (OR 0.89, 95% CI 0.40 to 1.98; figure 12), or long-term reoperation (OR 1.28, 95% CI 0.53 to 3.06; figure 13). No conclusions could be drawn from the single study.

Cost per patient (30-day)

Cost per patient was only evaluated in the IMPROVE study, which found the mean cost slightly less in the eEVAR treated arm after 30 days, £13 433 compared with £14 619 in the open repair group. The mean difference worked out to be £1186, favouring eEVAR, but as both trial arms had large SDs, the 95% CI was very wide, spanning £−2996.24 to £624.24. As only a single study reported on cost, no overall association could be determined (figure 14).

Open conversion

As open conversion can only be evaluated in the eEVAR treatment group, meta-analysis is not an appropriate way to compare this outcome between the three studies. The AJAX reported 10 cases of open conversion in the 57 (17.5%) participants randomised to eEVAR. Hinchcliffe had 1 open conversions out of the 15 (6.7%) randomised to eEVAR, and the IMPROVE study only had 4 out of 316 (1.3%) randomised, which is far lower than the other two trials. This could also be the result of the 13% of randomised participants in the IMPROVE study that did not have RAAA, but rather 22 participants had symptomatic non-ruptured AAA, 10 had no AAA and 45 had asymptomatic AAA or another final diagnosis and also 84 participants randomised to eEVAR were determined unsuitable for the procedure and moved to open repair, but were not considered open conversion.

Table 5 contains perioperative and postoperative patient characteristics that were not considered as outcomes in this review, but are of interest when comparing eEVAR with open repair, and also for comparisons between the trials. The table addresses time spent waiting for surgical intervention, time in operating theatre, blood loss during operation and length of time spent in hospital. As two studies used median and IQR and one study reported using mean and SD, the findings could not be compared quantitatively, but rather used for anecdotal analysis.

DISCUSSION

The three studies eligible for inclusion in this review were of good quality. The evidence gathered was relevant but there were few data to support an association, and other outcomes of interest were not acknowledged within the studies, such as minor complications and quality of life. Although all potential sources of data were carefully vetted, it remains possible that relevant data were not published, or that were not found in the search.

All three included studies did require a clinical diagnosis of RAAA for inclusion in the study, yet the IMPROVE study, on start of intervention, found that 77 (13%) of their included, randomised participants did not have RAAA; 22 had symptomatic non-ruptured AAA, 10 had no AAA and 45 had asymptomatic AAA or another final diagnosis. The authors of the IMPROVE trial claimed this method was a more ‘real-world’ approach to the issue. While this may not effect the overall outcomes, it is of concern. Also, the IMPROVE trial did not assess eEVAR suitability prior to randomisation, which resulted in 84 participants randomised to eEVAR not being suitable for the procedure and transferred to open repair. Hinchliffe et al also did not select participants for their suitability for both eEVAR and open repair prior to randomisation, and one patient randomised to eEVAR was transferred to open repair. The AJAX trial evaluated a more selected study population of participants suitable for both eEVAR and open repair. These methodological differences could possibly alter the applicability of the evidence as the results could be aimed at different populations.
Figure 10  Amputation after emergency endovascular aneurysm repair (eEVAR) versus open repair.

Figure 11  Respiratory failure of emergency endovascular aneurysm repair (eEVAR) versus open repair.

Figure 12  Mortality at 6 month for emergency endovascular aneurysm repair (eEVAR) versus open repair.

Figure 13  Reoperation at 6 months for emergency endovascular aneurysm repair (eEVAR) versus open repair.

Figure 14  Cost per patient (30 days) of emergency endovascular aneurysm repair (eEVAR) versus open repair.

Table 5  The perioperative details of the three studies

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>AJAX (median, IQR)</th>
<th>Hinchliffe (median, IQR)</th>
<th>IMPROVE (mean, SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time waiting for procedure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVAR</td>
<td>74 min (39–126)</td>
<td>93 min (±370)</td>
<td></td>
</tr>
<tr>
<td>Open repair</td>
<td>45 min (35–70)</td>
<td>73 min (±157)</td>
<td></td>
</tr>
<tr>
<td>Time in operating theatre</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVAR</td>
<td>185 min (160–236)</td>
<td>160 min (150–234)</td>
<td>156 min (±100)</td>
</tr>
<tr>
<td>Open repair</td>
<td>157 min (136–194)</td>
<td>150 min (141–204)</td>
<td>180 min (±107)</td>
</tr>
<tr>
<td>Blood loss during operation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVAR</td>
<td>500 mL (200–1375)</td>
<td>200 mL (163–450)</td>
<td></td>
</tr>
<tr>
<td>Open repair</td>
<td>3500 mL (1000–4600)</td>
<td>2100 mL (1150–3985)</td>
<td></td>
</tr>
<tr>
<td>Length of hospital stay</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVAR</td>
<td>9 days (4–21)</td>
<td>10 days (6–28)</td>
<td>9.8 days (±9.0)</td>
</tr>
<tr>
<td>Open repair</td>
<td>13 days (5–21)</td>
<td>12 days (4–52)</td>
<td>12.2 days (±10.2)</td>
</tr>
</tbody>
</table>

EVAR, endovascular aneurysm repair.
This is the first systematic review, evaluating only studies that are prospective, RCTs, comparing eEVAR with open repair in patients with RAAA. There have been other studies, including several systematic reviews, that have addressed eEVAR versus open repair in patients with RAAA, but these have mostly observational, non-randomised studies, many of which were retrospective. These types of studies are more likely subject to bias, compared with RCTs.

Visser et al\(^5\) included 10 observational studies comparing patients who underwent eEVAR or open surgery, looking at short-term outcomes. A crude random-effects model for 30-day mortality, comparing eEVAR with open repair found that when patient haemodynamic condition at presentation was included in the model, that both modalities are suitable for treatment of patients with RAAA, and that eEVAR may possibly have a higher 30-day survival. The crude and adjusted ORs showed a stronger relationship between lower mortality in the eEVAR group than our own results for the 30-day mortality outcome, which showed no difference between the two interventions. The Visser study also evaluated a composite, systemic complications outcome, which found a lower point estimate within the eEVAR group, 28% (95% CI 17% to 48%), compared with open repair, 56% (95% CI 37% to 85%), indicating fewer complications within the eEVAR group.\(^5\) The present study did not have sufficient data on complications to compare with these results, nor was a composite, systemic complications outcome included.

The Takagi and Umemoto\(^5\) meta-analysis included 11 RCTs or risk-adjusted observational studies, with a total of 42 888 patients. Inclusion criteria required studies to be RCTs or risk-adjusted observational comparative studies. This review included 1 RCT and 10 observational studies. While the present mortality results showed little difference between eEVAR and open repair, the Takagi study showed a strong relationship of lower mortality in the eEVAR arm (\(p<0.0001\)).\(^5\)

Another meta-analysis included 18 studies, of which 11 were retrospective, and 2 of the RCTs in the present review.\(^5\) The review demonstrated a lower mortality and shorter length of stay in the eEVAR group (\(p=0.01\)). However, the heterogeneity of study designs in the meta-analysis significantly detracts from the quality of the results and conclusions.

Another review included 41 studies, of which 2 were RCTs, and the remaining were observational, population-based studies, with a total of 59 941 participants.\(^5\) The authors found a statistically significant lower mortality for the participants who underwent eEVAR, compared with open repair, OR 0.56 (95% CI 0.50 to 0.64; \(p<0.00001\)). The mortality outcome showed a strong mortality odds reduction for the eEVAR group where our study found little difference. Many of the complications evaluated in the Antoniou study also showed lower risk in the eEVAR group. The authors also evaluated cardiac complications, showing a borderline statistically significant risk difference favouring eEVAR (−0.02, 95% CI −0.03 to 0.00; \(p=0.05\)). The findings of complication outcomes in our review cannot currently be compared as there is not enough data to make any definitive conclusions.

Owing to a lack of data, this present review, using only prospective RCTs, was unable to determine superiority of either eEVAR or open repair for RAAA. Previous retrospective studies have suggested a significant survival advantage in case-control study designs for patients undergoing eEVAR. However, the key difference between eEVAR and an open historical comparative group is the anatomical configuration. Favourable anatomy to EVAR may preselect patients who ultimately will do well despite the modality of surgery. So when only these selected patients are included in a RCT, no difference is found in outcomes. Based on these findings, it would be difficult to justify complex endovascular repair of juxtarenal or thoracoabdominal aneurysms in the emergency setting. Caution also needs to be voiced in transferring a patient with RAAA from a centre which can provide open repair, to an alternative centre equipped to provide both open and endovascular repair, with a consequent delay in treatment. In addition, while volume outcome analysis supports centralisation, the provision of both modes of RAAA repair does not.

Further trials to evaluate the role of eEVAR in the treatment of RAAA are required, addressing all outcome measures. The evidence from non-randomised studies, showing reduced mortality in selected patients deemed suitable for endovascular repair, may raise ethical concerns in relation to randomising these patients to open repair. It may, therefore, be necessary to stratify the patients according to anatomical criteria at the time of CT diagnosis, so that the studies are powered for subgroups analysis.

Acknowledgements The authors wish to thank the Cochrane PVD Group for their support in approving this publication of the recent Cochrane Review (CD005261). This article is based on a Cochrane Review published in the Cochrane Database of Systematic Reviews (CDSR) 2014, Issue 7, DOI: 10.1002/14651858.CD005261 (see http://www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the CDSR should be consulted for the most recent version of the review.

Contributors This paper is an update of the original Cochrane review in 2007. SAB, DWH, PHB, PKE, FK and Bedenis R were involved in study design. SAB and Bedenis R were involved in data collection and data analysis. SAB, DWH, PHB, PKE, FK and Bedenis R were involved in writing the manuscript and final approval of the manuscript.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


33. Powell JT, Hincliffe RJ, Thompson MM, et al. Improve trial investigators. Observations from the IMPROVE trial concerning the...


